Key result
SGLT2 inhibitors show promise in reducing cancer therapy-related heart failure, hospitalizations, and overall mortality.
Why the study?
Anticancer therapies, particularly anthracyclines, carry substantial cardiotoxicity risks, but evidence suggests SGLT2 inhibitors may mitigate cancer therapy-related cardiovascular toxicity.
Do SGLT2 inhibitors prevent or mitigate cancer therapy-related cardiovascular toxicity in patients undergoing cancer therapies?
Do SGLT2 inhibitors prevent or mitigate cancer therapy-related cardiovascular toxicity in patients undergoing cancer therapies?
SGLT2 inhibitors represent a promising, emerging strategy for the prevention and mitigation of cancer therapy-related cardiovascular toxicity, potentially improving long-term outcomes in cardio-oncology.
May support SGLT2 inhibitor evaluation in cardio-oncology; leaves open prospective randomized confirmation before practice change.
Sodium-glucose cotransporter-2 inhibitors (SGLT2i), initially developed for the management of type 2 diabetes mellitus, have demonstrated significant nephroprotective and cardioprotective effects. These benefits have led to their inclusion in heart failure (HF) management guidelines, irrespective of glycemic status and left ventricular ejection fraction (LVEF). Various anticancer therapies, particularly anthracyclines, are associated with substantial cardiotoxicity risks, resulting in cancer therapy-related cardiovascular toxicity (CTR-CVT). Promising evidence from preclinical and observational studies indicates that SGLT2i may mitigate cardiotoxic effects of cancer therapy by alleviating LVEF decline, reducing HF incidence and hospitalizations, and lowering overall mortality. Moreover, improved survival has been reported in patients with various malignancies. The current review explores the potential applications of SGLT2i in the prevention of CTR-CVT, highlights their possible mechanisms of cardioprotection, discusses the published evidence, and emphasizes the need for the results from ongoing randomized controlled trials to establish SGLT2i efficacy and safety in cardio-oncology patients.
No takes yet. Share an insight, caveat, or question.
Zebrowska et al. (2025) conducted a review in Cancer therapy-related cardiovascular toxicity (CTR-CVT). SGLT2 inhibitors was evaluated on Mitigation of cardiotoxic effects (LVEF decline, HF incidence, and mortality). SGLT2 inhibitors show promising potential in mitigating cancer therapy-related cardiovascular toxicity by reducing heart failure incidence, hospitalizations, and overall mortality across various malignancies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: